A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...

Learn how new oral GLP-1 weight loss pills work, how they compare with injections, and how the next generation of “small ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...

Fact checked by Nick Blackmer The first GLP-1 pill for weight loss is now available, offering a daily oral alternative to injectable drugs.Studies show the pill is about as effective as shots, but it ...

Learn more about GLP-1 pills and how they may be more convenient and cost-effective than the injections.

Tirzepatide users on hormone therapy had added improvements in weight, cardiometabolic mar ...

Add Yahoo as a preferred source to see more of our stories on Google. Having an oral version of the medication, which had only been available as an injectable until now, is a “very big deal,” says ...

At this year’s meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Eli Lilly sought to bolster the case for its oral GLP-1 orforglipron, showcasing more of the drug's ...

GLP-1 medications can create opportunity for change—but environment determines what lasts. Discover how context shapes habits ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...